Thomas Leggett

Chief Financial Officer, Axcella Health (United States).

Companies

Stoke Therapeutics, Inc.Chief financial officer May 17, 2024 to now¹
Research Alliance Corp. IIBoard member Mar 17, 2021 to Mar 17, 2021²
Black Diamond Therapeutics, Inc.Chief financial officer Jan 29, 2020 to Feb 19, 2021³
Axcella Health (United States)Chief financial officer May 8, 2019 to May 8, 2019⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Stoke Therapeutics, Inc. STOK10,172 shares⁵$248.0K at $24.39Mar 18, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

Mar 18, 2026Sold 37 shares at $32.85 of Stoke Therapeutics, Inc.⁵
Mar 18, 2026Sold 172 shares at $31.79 of Stoke Therapeutics, Inc.⁵
Mar 18, 2026Sold 2,173 shares at $31.28 of Stoke Therapeutics, Inc.⁵
Mar 17, 2026Sold 922 shares at $33.38 of Stoke Therapeutics, Inc.⁵
Mar 17, 2026Sold 1,274 shares at $32.74 of Stoke Therapeutics, Inc.⁵
Mar 15, 2026Exercised options 14,750 shares of Stoke Therapeutics, Inc.⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARStoke Therapeutics, Inc., Chief financial officer
2
SEC EDGARResearch Alliance Corp. II, Board member
3
SEC EDGARBlack Diamond Therapeutics, Inc., Chief financial officer
4
SEC EDGARAxcella Health (United States), Chief financial officer
5
SEC EDGARStoke Therapeutics, Inc. shares after the filing of Mar 18, 2026
6
SEC EDGARForm 4 filed Mar 17, 2026